Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies

Drug Development and Industrial Pharmacy

Volumn 33, Issue 5, 2007, Pages 569-575

  Zhang, Dianrui ^a,b   Tan, Tianwei ^a   Gao, Lei ^b   Zhao, Wenfa ^b   Wang, Peng ^b  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Azithromycin; High pressure homogenization; Lyophilisation; Nanosuspensions

Indexed keywords

AZITHROMYCIN; NANOPARTICLE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FREEZE DRYING; GASTROINTESTINAL TRACT; HOMOGENATE; LOADING DRUG DOSE; NANOTECHNOLOGY; PHYSICAL CHEMISTRY; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; PRESSURE; SOLUBILITY; SURFACE-ACTIVE AGENTS; SUSPENSIONS; X-RAY DIFFRACTION;

EID: 34249323769     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600975147     Document Type: Article

References (17)

1. Amsden, G. W. (2001). Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents, 18(11), 11-15.
2. Bernhard, H. L., Böhm, & Müller, R. H. (1999). Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm. Sci. & Tech. Today, 2(8), 336-339.
3. Chawla J. S., & Amiji M. M. (2002). Biodegradable poly (epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int. J. Pharm., 249,127-38.
4. Corrigan, D. O., Healy, A. M., & Corrigan, O. I. (2003). The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int. J. Pharm., 262(1-2), 125-137.
5. Dubernet, C. (1995). Thermoanalysis of microspheres. Thermochim. Acta, 248, 259-269.
6. Glenda, T., Dennis, P., & Arlene, R. (2002).The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. Int. J. Antimicrob. Agents, 19, 189-194.
7. Grau, M. J., Kayser, O., & Müller, R. H. (2000). Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm., 196(1),155-157.
8. Hancock, B. C., Carlson, G. T., Ladipo, D. D., Langdon, B. A., & Mullarney, M. P. (2002). Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int. J. Pharm., 241(1), 73-85.
9. Hoepelman, I. M., & Schneider, M. M. E. (1995). Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents, 5, 145-167.
10. Jacobs C., Kayser O., Müller, R. H. (2001). Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int. J. Pharm., 214(1-2), 3-7.
11. Keck, C. M., & Müller, R. H. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm., 62, 3-16.
12. Kocbek, P., Baumgartner, S., & Kristl, J. (2006). Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. Pharmac. Nanotech., 312(1-2), 179-186.
13. Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M., Zackrisson, A., & Olsson, U. (2006). Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir, 22(3), 906-910.
14. Moschwitzer, J., Achleitner, G., Pomper, H., & Müller, R. H. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension techno. Eur. J. Pharm. Biopharm., 58(3), 615-619.
15. Müller, R. H., & Jacobs C. (2002). Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm., 237(1-2), 151-161.
16. Müller, R. H., Jacobs, C., & Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev., 47(1), 3-19.
17. Müller, R. H., & Peters, K. (1998). Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique. Int. J. Pharm., 160, 229-237.